Cerevel Therapeutics Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., June 29, 2021 (GLOBE NEWSWIRE) — Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of…
Pharmaceuticals, Biotechnology and Life Sciences
CAMBRIDGE, Mass., June 29, 2021 (GLOBE NEWSWIRE) — Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of…
PALISADE-1 Phase 3 trial underway to evaluate PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder…
IRVINE, Calif., June 29, 2021 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused…
FORT LAUDERDALE, Fla., June 29, 2021 (GLOBE NEWSWIRE) — Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”),…
Topline results for Phase 3 Pivotal Cardigan I and Cardigan II studies expected in Q4 2021BOULDER, Colo., June 29, 2021…
— Recorded Fourth Quarter Revenue of $27.6 Million and Annual Revenue of $95.9 Million — — Achieved Four Consecutive Quarters…
NEW HAVEN, Conn., June 29, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies Inc. (“Bioasis” or the “Company”) (TSX.V:BTI; OTCQB:BIOAF), a pre-clinical,…
UNIONDALE, N.Y., June 29, 2021 (GLOBE NEWSWIRE) — Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery,…
Open Investigational New Drug Application (IND) with U.S. Food and Drug Administration (FDA) for Phase III study of nomacopan in…
AdCOVID was well tolerated but did not stimulate an adequate immune response in healthy volunteersAltimmune will discontinue further development of…